Trial Profile
A randomized phase III trial of S-1 versus S-1 plus irinotecan in advanced gastric cancer.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 14 Jan 2019
Price :
$35
*
At a glance
- Drugs Gimeracil/oteracil/tegafur (Primary) ; Irinotecan (Primary)
- Indications Gastric cancer
- Focus Therapeutic Use
- Sponsors Daiichi Sankyo Company; Yakult Honsha
- 16 Jun 2016 New trial record